Suven Life Sciences has completed enrollment of patients with Last-Patient-In Goal for its Phase 2 POC study of SUVN-502 for moderate Alzheimer’s disease. The company expects to report the top-line data of this study by July/August 2019 time frame.
This randomized, double-blind, placebo-controlled study is evaluating the efficacy and safety of two doses of SUVN-502 in moderate Alzheimer’s Disease patients who are taking both Aricept (donepezil) and Namenda (memantine). Study duration is 30 weeks. This is the first ever study to evaluate a triple combination therapy for moderate Alzheimer’s disease patients.
There is an urgent need for treatment options for patients with Alzheimer’s disease (AD) dementia since there are no new drugs discovered or developed from 2003 till now.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.
